Abstract Details

Title No Association Between Carotid Artery Atherosclerosis and Hyoid Proximity: Results from a Cross-sectional and Longitudinal Cohort Study

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P1 - Poster Session 1 (5:30 PM-6:30 PM)

Poster/Presentation
Number 3-059

Objective

To identify a potentially causal relationship between hyoid bone proximity and cervical carotid atherosclerosis.

Background

Cervical internal carotid artery (ICA) atherosclerotic plaque and stenosis is often asymmetric. Hyoid bone proximity to the cervical ICA varies from one side to the other and may increase the risk of traumatic endothelial injury, accelerate plaque formation, and contribute to asymmetric stenosis.

Design/Methods A retrospective cross-sectional and longitudinal cohort design evaluated consecutive adult patients at 3 hospitals who underwent computed tomography angiography (CTA) of the neck >/=2 calendar years apart (01/2000-07/2017). Plaque thickness, luminal stenosis, and their progression over time were compared between sides for each patient by hyoid-ICA distance.

Results Sixty-six patients were included, with a median age of 64 years (IQR 53-73), 37 (56.1%) female, and 28 (42.4%) non-White. The median hyoid-ICA distance was 3.06mm (IQR 1.27-6.20mm), and the median plaque thickness was 3.5mm (IQR 2-4). ICA plaque thickness was no different on the side with the shorter hyoid-ICA distance (median 2.5mm [IQR 1-4] vs. 3.0mm [IQR 2-4], p=0.366), nor was it different when hyoid-ICA distances were grouped by quartile after adjustment for statin use, ICA angle, and delay to repeat CTA (p=0.795). After a median follow-up of 1002 days (range 392-3,397 days), the change in plaque thickness was no different between the ICA with the shorter hyoid-ICA distance compared to the side further (median change 0.5cm [IQR 0 – 1] vs. 0.0cm [IQR -0.5 – 0.5], p=0.209).

Conclusions

The presence and progression of atherosclerotic plaque appeared unrelated to hyoid-ICA distance in this cross-sectional and longitudinal cohort study.

Authors/Disclosures
James E. Siegler III, MD (University of Chicago) PRESENTER	Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Siegler has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bayer. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Serb. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Wallaby Phenox. Dr. Siegler has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Stroke: Vascular and Interventional Neurology. Dr. Siegler has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Precision Medicine, LLC. The institution of Dr. Siegler has received research support from Philips. The institution of Dr. Siegler has received research support from Medtronic.
Glenn L. Konsky, DO (St. Luke's University Health Network)	No disclosure on file
Christopher Renner, MD (Wellspan Medical Group)	No disclosure on file
	No disclosure on file
	No disclosure on file
Brett L. Cucchiara, MD (Hosp Uni of Pennsylvania)	Dr. Cucchiara has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Elseiver. Dr. Cucchiara has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Bayer. Dr. Cucchiara has received publishing royalties from a publication relating to health care.
Steven R. Messe, MD, FAHA, FAAN (Hospital of the University of Pennsylvania)	Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Terumo. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for WL Gore. The institution of Dr. Messe has received research support from WL Gore. The institution of Dr. Messe has received research support from Mallinkrodt. The institution of Dr. Messe has received research support from Biogen. Dr. Messe has received intellectual property interests from a discovery or technology relating to health care. Dr. Messe has received publishing royalties from a publication relating to health care. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving as a Clinical Event Committee for the CONFORMAL left atrial appendage occlusion trial with Yale Cardiovascular Research Group.

��ɫ��

��ɫ��